DocGo Inc. (DCGO) Earnings Call Transcript & Summary
November 7, 2022
Earnings Call Speaker Segments
Mike Cole
executiveThank you, operator. Before I hand things over to management, I'd like to offer a few comments regarding forward-looking statements. Everything shared on this conference call that isn't a historical fact counts as a forward-looking statement. Terms such as anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, along with other comparable expressions, typically serve to flag these forward-looking statements. Such forward-looking statements don't constitute guarantees regarding future performance and could involve, and are subject to, particular risks, uncertainties, and additional factors that might impact DocGo's business, financial condition, and other operating results. Among these are, though not exclusively, the risk factors and other qualifications found in DocGo's annual report on Form 10-K, quarterly reports filed on Form 10-Q, and other reports and statements DocGo files with the SEC, to which your attention is directed. Actual outcomes and results could differ materially from what these forward-looking statements express or imply. Furthermore, today's call includes references to non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measures appear in our earnings release, posted on our website, docgo.com, and also in our filings with the Securities and Exchange Commission. The information shared on this call is accurate only as of the date discussed. Investors shouldn't assume that statements will stay relevant and operative at a later time. We assume no obligation to update any information discussed on this call in the future. At this point, it's my pleasure to turn the call over to Mr. Stan Vashovsky, CEO, Chairman, and Co-founder of DocGo. Stan, please go ahead.
Stan Vashovsky
executiveThanks, Mike, and I appreciate everyone being on today's call. Our third quarter was yet another stretch of solid operational performance, with revenues climbing 22% compared to the same period last year, reaching $104.3 million. Thanks to sustained sales momentum along with contributions from acquisitions, we've raised our full year 2022 revenue outlook to $430 million-$440 million, which is up from the earlier $425 million-$435 million range; similarly, we're lifting our 2022 adjusted EBITDA guidance to $41 million-$46 million, compared with the prior $40 million-$45 million range. On the whole, we succeeded remarkably in moving our mass COVID testing clients over to a variety of other long-term mobile health programs. We figure mass COVID testing made up a mid-single digits percentage share of total revenues in the third quarter, versus roughly 35% of revenue in Q3 of 2021, and the final one of those contracts wrapped up in September of this year. A lot of these new programs focus on population health, which has turned into a really hot topic among municipal, state, and federal programs. We're witnessing significantly larger budgets in this area, and DocGo's low-cost health delivery model fits perfectly to address this need moving forward. Right now, I'll hand the call over to our President, Anthony Capone, so he can talk about operational progress and our growth initiatives as we move into 2023. Anthony.
Anthony Capone
executiveI appreciate that, Stan, and I want to thank everyone for being on today's call. From an operations standpoint, this is a truly amazing and thrilling moment for DocGo. We're not just expanding the mobile health and medical transport operations we already have — we're also opening up new markets that we believe will fuel our next phase of growth in 2023. At this point, DocGo has firmed up what it offers and accumulated enough know-how across every service line to back a strategy built for scale. It matters to grasp, at its core, why DocGo's mobile medical approach is such a vital piece of what society will look like going forward. Historically, physicians delivered the bulk of patient care inside the home; that made care more thorough, since a person's surroundings and relatives were woven straight into the treatment plan. Then society shifted physicians into hospitals — not because that was superior, but because it saved more money. It simply stopped being workable for highly compensated clinicians to drive out to each person's residence. DocGo's approach fixes that by deploying well-trained, economical clinicians who deliver care to patients wherever they are, whenever they need it, all while under live video oversight from an off-site advanced medical provider. This approach to delivering care—making it both reasonably priced and top-notch in quality—allows us to return to an era when treatment addressed the entire person, and it does so at a cost that's within reach for most people. That creative spirit behind it keeps earning more and more attention. Take, for example, the SHOW initiative that DocGo operates alongside New York City; it secured a spot as a finalist in Fast Company's World Changing Ideas Awards, and at this moment it's also a finalist for the UCSF Digital Health Awards. With Dr. Jim Powell joining us as the incoming head of our Managed Clinical Practice Group, DocGo's advances in clinical care are going to accelerate further. Dr. Powell isn't just a celebrated clinical innovator — we consider him among the finest primary care physicians anywhere in the country. Lee Bienstock, who came to us from Google as Chief Operating Officer earlier this year, has shifted our growth efforts into a much higher gear. During the past quarter, we experienced strong organic growth in both our mobile health and transport divisions; back in August, we kicked off a pilot with Dollar General in Tennessee, delivering primary and urgent care services to their shoppers through a mobile health clinic stationed in their store parking lots. The pilot phase is still young, but given Dollar General's enormous nationwide footprint, we're enthusiastic about what this relationship could become. Back in September, the last of our large-scale COVID testing agreements was converted into a community pharmacy initiative that provides medications such as PAXLOVID. I'm pleased to report that at this moment, we are not party to any active mass COVID testing contracts. There remains a collection of standby surge contracts for mass COVID testing held by DocGo, which could be activated if a surge in COVID cases were to happen; however, we have not made plans for any such resurgence, and our financial forecast does not account for it. September was also when we began providing health care to the migrant population that has been arriving in New York City — the very situation that has recently been covered in the news. Since then, what began as a migrant health initiative has expanded into a long-term agreement under which DocGo delivers a broad array of services to asylum seekers living in their shelters. One thing worth flagging: every one of these new engagements carries higher costs at the outset. Those early launch costs stem mainly from temporarily elevated labor rates, plus expenses tied to the greater management oversight that new project launches require. Once the first 30 days pass, these initial launch expenses start to come down, and they completely level off after 90 to 120 days. Beyond organic growth, we've seen considerable success from our approach to acquisitions. Ben Sherman, our EVP of Corporate Development, headed up that initiative, and during Q3 we added three companies with strong potential. The approach we take — and the lens through which we view synergy — is that once a deal closes, the business we've acquired can immediately drive substantial revenue through the customers DocGo already serves. Take Exceptional Medical Transport: it's a textbook case. Jefferson Health now ranks as Exceptional's top customer, and DocGo has held a strategic partnership with that organization for over three years. Another case in point: New York City Health + Hospitals now stands as one of Government Medical Services' biggest customers — a relationship DocGo has spent time building into a robust one. We've shown our team can do more than just pick up licenses and capabilities at a bargain — we can also turn that potential worth into results, taking a larger piece of the addressable market as we go. That said, technology remains the bedrock of this company. This year we've put more than $3 million into it, and in the third quarter alone that figure came to over $1 million, all to develop advanced proprietary technology that our very skilled clinicians rely on. Led by Hawk Newton, our Chief Technology Officer, alongside Aaron Severs, our Chief Product Officer, our engineering team — among the best anywhere — turned out some remarkable tech during the quarter. Not only did they manage to bring DocGo's B2C on-demand mobile healthcare app to the iOS App Store, but they also succeeded in getting DocGo's B2B mobile health app into the Epic App Orchard. The fourth quarter of 2023 promises to be even more thrilling, as we are making our way into the remote patient monitoring, or RPM, sector; at the start of October, we shared news that our inaugural pilot program tied to this initiative had been launched alongside West PACE, based in San Diego. West PACE is an initiative centered on person-centric care that brings down emergency room visits, unnecessary hospital admissions, and long-term nursing home placements, all while lowering the cost of care. Naturally, this fits perfectly with how DocGo delivers care, and we're extremely enthusiastic about this partnership within that sector. One big reason the remote patient monitoring space appeals so strongly to DocGo is that we can do more than just keep tabs on patients dealing with chronic conditions — we can also deploy DocGo's mobile clinicians so that, wherever feasible, treatment happens right at home, helping us sidestep expensive and needless hospital stays. On top of that, when medical transportation is needed, that's another service we're able to offer. Because of the contracts we've finalized with payers, DocGo now reaches over 10 million covered lives. We plan to leverage those relationships to attract additional remote patient monitoring customers. In this sector, DocGo holds a distinctive place, able to deliver complete solutions that span monitoring, telehealth, in-home visits from more than 4,000 clinicians, and patient transportation whenever it's required. We intend to put substantial money into this area, through M&A as well as by drawing on over 50 individuals within our product and engineering group, so that we build a meaningful footprint in this market. During the prior quarter, with Lee guiding the effort, we launched a major campaign to pursue bigger RFP possibilities. How long it takes to move through such RFP processes differs, yet typically most take roughly half a year. Since the volume of our work in this channel rose sharply starting earlier in the summer, we anticipate reaping the rewards of that work at the start of 2023. Among the kinds of projects we're submitting bids for are supplying mobile infectious disease response teams in a large metropolitan area, supplying medical transportation for a big national payer, and, as a separate matter, a sizable hospital network located in the Northeast. Naturally, we cannot guarantee that these endeavors will pan out. We're eager about what this channel might add next year. The expanding set of payer ties we've built also holds enormous promise as we move into 2023; during the third quarter, we revealed a fresh arrangement with Cigna to deliver urgent care along with annual physical-style services to that company's members in specific parts of New York and New Jersey. Should it work out, relationships like these can scale up quickly. Our aim is to keep cultivating these ties, moving them beyond the present pilot stage until we become trusted vendors serving their wide member bases throughout the U.S. Over time, DocGo has shown a steady knack for getting an opening with prominent customers, meeting our targets, and turning those customers into major revenue-producing relationships. Heading into 2023, that's precisely what we're striving for: keep expanding our core business while sowing seeds for substantial growth possibilities in a way that limits risk. On that front, we're sitting in an excellent spot. Right now, I'll pass things to Andre so he can go over the quarter's financials. Andre.
Andre Oberholzer
executiveAppreciate that, Anthony, and hello to everybody this afternoon. Looking at Q3 2022, we brought in $104.3 million in total revenue — up 22% compared with the $85.8 million recorded during the same quarter in 2021. That growth at the top line, measured year over year, was driven by a combination of sales at existing locations, bringing new customers on board, and growth through acquisitions, specifically by picking up licenses and capabilities in a number of markets. Revenue from mobile health during the third quarter of 2022 reached $76.6 million, up from $67.9 million in Q3 2021 — a gain of about 13%. As for mass COVID testing-related revenue, it accounted for a mid-single-digit percentage of overall revenue in Q3, whereas back in the third quarter of 2021 it represented roughly 35%. Transportation for medical purposes brought in $27.7 million, which is roughly 55% higher than the $17.9 million seen in Q3 of 2021. In the third quarter of this year, mobile health made up 73% of overall revenue, versus 79% a year earlier, while transportation accounted for the remainder. U.K. market revenue climbed 15%, hitting $3 million during Q3 of this year, which amounts to about 3% of all revenue. For the third quarter of 2022, net income came to $2.5 million — a major gain compared with the $800,000 in net income posted during the same quarter last year. Strip out a $1.8 million loss tied to remeasuring warrant liabilities in this year's third quarter, and net income would have totaled $4.3 million. Higher revenues this quarter, plus an improved overall gross margin, drove the gain in net income, and some infrastructure-related overhead expenses gave us leverage since they grew at a slower pace than revenues. For Q3 2022, total gross margin percentage reached 31.7%, up from 30.1% in the comparable 2021 period. Worth noting: even with inflation squeezing labor costs and other cost of sales items such as fuel and medical supplies, DocGo still delivered this year-over-year gross margin gain. A 1.6% rise in overall gross margin percentage came mainly from the transportation segment, with gross margins climbing to 23.2% in our third quarter this year from 7.1% in Q3 last year. This gain reflected greater volumes and higher average trip prices, along with reduced average hourly wages as recent market wage pressures started easing and the company managed staffing more effectively to cut overtime hours among field employees. Those factors outweighed the increase in average fuel costs. For the mobile health segment, gross margins stood at 34.8% in Q3 of this year, versus 36.1% in the third quarter of 2022. This slight decline came about because several of the company's new projects this year carried higher start-up costs. Our total cash and cash equivalents, restricted cash included, stood at $179.4 million on September 30, 2022, versus $179.1 million at the close of fiscal 2021. Even after spending roughly $35.5 million on licenses and on bringing new services into additional markets, our cash position stayed basically flat. Net cash generated by operations during the first nine months of 2022 was positive, reaching $31.3 million, whereas the same period a year earlier produced $6.9 million in cash from operations. If you set aside vehicle finance leases totaling $9 million, our outstanding debt stood at $2.1 million when Q2 closed, versus $1.9 million when last year ended. Turning to how inflation affects us, as we've said before, there are two big expense areas where it could meaningfully move our results. The 2022 guidance we gave at the start of the year bakes in an assumption that labor's average hourly cost would rise roughly 7% relative to 2021's already elevated labor rates, and that gas would average $4.30 per gallon. Looking at the third quarter of 2022, our realized average hourly labor cost exceeded the prior year's actual figure, though it stayed under our forecast. Meanwhile, fuel's average per-gallon price, having declined from second-quarter levels, stood well above the year-ago number but landed extremely close to our projection. During this year's Q3, steeper gas expenses pushed gross margin roughly 30 basis points lower than in Q3 2021, and compared with our 2022 assumptions, the impact amounted to only 2 basis points. Turning to labor, the average hourly rate climbed just shy of 2% versus the same period last year, reducing margins by 36 basis points in this year's Q3. With that being said, the real average rate we paid per hour wound up under what we had assumed for 2022, which gave us a favorable difference of about 163 basis points relative to the gross margin figure we had projected. When it came to Q3 of 2022, adjusted EBITDA landed at $8.4 million, which works out to slightly over 8% of revenue, versus $4 million, or 4.7% of revenue, during the comparable quarter last year. It's worth remembering that adjusted EBITDA isn't a GAAP measure — it captures earnings prior to interest, tax, depreciation, amortization, stock-based compensation, warrant, and finance lease liability revaluations, along with other non-recurring expenses. Our earnings release contains a reconciliation of adjusted EBITDA to net income; for the nine months that ended September 30, 2022, total revenue reached $331.7 million, a 68% increase over the $197.4 million of total revenue for the nine months that ended September 30, 2021. Adjusted EBITDA for the nine months that ended September 30, 2022 was $34.5 million, a substantial gain over the $7.8 million of adjusted EBITDA in the comparable period a year ago. Net income for the nine months that ended September 2022 was $23.6 million, a substantial gain over the $1.1 million net loss in the comparable period a year ago. On the 2022 outlook: we see customer demand remaining robust across both mobile health and transportation services. Given the strength of our performance to date, as Stan mentioned earlier, we're increasing our revenue guidance to a range of $430 million to $440 million, up from the $425 million-$435 million we had previously projected. In addition, we're raising our adjusted EBITDA guidance to $41 million-$46 million, versus the $40 million-$45 million we guided earlier. This increase reflects a combination of organic growth and additional acquisition activity. That works out to revenue growth of 35%-38% year-over-year, and adjusted EBITDA as a percentage of revenue should improve to almost 10% this year, versus 7.9% in fiscal 2021. On segment revenues, we anticipate the mobile health segment will keep delivering roughly 75% of revenues, with medical transportation making up the rest. That's all I have to say. Now I'd like to turn things back over to Stan for his closing remarks. Thank you. Stan?
Stan Vashovsky
executiveThanks, Andre. Ahead of taking questions on this call, I want to address the CEO succession plan we shared in today's press release covering our earnings. Starting December 31st, I'm retiring — I'll step away from my roles as CEO and as Chairman of the Board of Directors. At that point, our President, Anthony Capone, will take over as CEO, and I've committed to helping the company until the close of 2023 so the handover goes smoothly. Ely Tendler — a board member of long standing and one of our Co-founders — will move into the Chairman position on the board. Looking back at the past seven years, I feel enormous pride in what we've achieved, and I genuinely believe our strongest days still lie in front of us. A lot of us figured Anthony would eventually move into the CEO seat, and what he's delivered as President has played a major part in getting us where we are today. Anthony has been key to bringing state-of-the-art technology into our offerings, which genuinely differentiates us and gives us a durable edge in the marketplace. I have complete faith in this company's ongoing growth and success; so with that, let's go ahead and take questions. Operator?
Matt Shea
analystHi there — is my audio coming through clearly for everyone?
Stan Vashovsky
executiveHi, that's great.
Matt Shea
analystAlright, sounds good. This is Matthew Shea, filling in for Ryan MacDonald. Thanks for fielding the question, and congratulations on a strong quarter — and, you know, all the best, Stan, with whatever comes after this.
Stan Vashovsky
executiveThanks, Matt.
Matt Shea
analystRegarding this particular quarter, it was encouraging to learn about a few of those RPM changes. I had interest in that Gary and Mary West PACE partnership. Could you perhaps give us some detail on which services you are delivering, and possibly the way you are being paid for those services? And then, how do you anticipate sort of applying the data and perhaps, you know, whatever other learnings produced by this relationship to inform your upcoming RPM approach or even any M&A in that area?
Stan Vashovsky
executiveYes. Anthony, do you want to handle that question?
Anthony Capone
executiveOf course. That's really a fantastic question. I appreciate you being with us, Matt. Our partnership with West PACE, which operates mostly around Southern California, began with a focus on urgent care; the goal there is stopping their capitated members from ending up back in the hospital or being admitted at all. How we accomplish that is by going to the scene and providing treatment right there. That aligns with the standard approach we use, with a lower-level clinician present and a higher-level clinician working remotely; the very same approach applies in that market and is uniform across the entire nation. In a similar way, the West PACE agreement we hold, like close to most of the agreements we sign, uses the identical pricing approach. Under it, we charge by the hour for what we provide. They'll request, "I'd like a single mobile health unit here, another one there, and one more over in that spot," and they compensate us at a set hourly rate, which somewhat shields our margin. Beyond that, we additionally receive — both in this instance and frequently — an extra incentive payment when we manage to achieve positive patient results; here, that positive result means cutting readmissions or cutting emergency room admissions relative to the baseline. In fact, we shared during our prior quarter — we still don't have the full data set for Q3, though for Q2 we did receive that incentive payment. We genuinely managed to lower, or even bring down, admission and readmission rates compared with the baseline. All of that information has proven extremely useful, and it's largely what pushed us earlier this year toward entering RPM. The information we gathered from it was then assembled into a white paper, and West PACE recently showcased it at their national PACE conference. PACE, as a lot of you are aware, ranks among the biggest semi-public, semi-private healthcare organizations across the United States. What's possible here is taking the identical program we run with West PACE in Southern California and rolling it out across every PACE site nationwide. Now, the RPM data rests on top of those urgent care services, working side by side with them. So instead of the old way of waiting for a patient to signal you and say, "Alright, I need your urgent care services," we now know because we're tracking them. We're able to spot elevated vitals, and we have the capability to start either a telehealth appointment and afterward, if needed, quickly go to the scene. RPM has truly turned into the basis that lets us occupy, in a sense, the driver's seat of healthcare rather than leaning back and letting it come to us. I trust that addresses what you were asking.
Matt Shea
analystUnderstood. Alright, it seems this is somewhat more focused on assisting with the development of value-based care frameworks instead of merely submitting claims to Medicare for CPT codes. That's logical. Perhaps switching topics, I believe another one of the exciting announcements involved the Epic integration, which now permits mobile health integration, expanding upon the transport component. That appears to be a good addition. Our checks have indicated that health systems aim to construct around their EHR, so this looks like a rather clever Trojan Horse approach to enter that space. I'm curious whether this is boosting your capacity to attach mobile health services onto transportation agreements with current health systems. And then, considering that, could we possibly consider the proportion of health systems presently that are transport customers and are likewise utilizing mobile health services? I'm just attempting to gauge what that potential looks like for you folks. Thanks.
Anthony Capone
executiveYeah. Thank you, Stan. Would you like me to handle that too?
Stan Vashovsky
executiveHey, as former CTO, who better to answer that question than you? Go ahead.
Anthony Capone
executiveAppreciate it. Yeah. Hats off to our tech folks for really grinding it out and getting that thing, you know, at long last completely live within the Epic App Orchard. That's a fairly significant advantage over competitors. I had just been on a phone call where I walked through exactly that alongside a big health system and the Epic App Orchard, since the ease of use is just so strong. Ordering that transition of care post-acute service takes simply one extra click, the same as the transport. Physically speaking, it's just extremely, extremely simple to pull off. These days we're writing every one of our agreements so that mobile health services get folded into them. That isn't a promise that everything is locked in, but a framework already exists through which the financial piece, the ordering piece, the clinical piece are already baked right in there. Every new contract of ours now carries that moving forward. It's a really substantial differentiator, and one reason we're able to do this is that we rely on this leased hour model together with the hospital. Essentially we make certain the hospitals grasp that the clinicians they have are leased; and now, whatever a hospital wants done, those leased clinicians are able to handle it. Of course, they can transport; that's what they mostly do. Whenever those leased clinicians are sitting in vehicles, in ambulances, they're able to take on anything else too. They can handle transition of care. They could handle post-surgery services. Since they're dedicated to you, they're yours. We're leasing them out to you. So get inventive about every single area where they might help your health system. Looking ahead, honestly, I haven't come across any health systems that wouldn't also want that kind of capability, wrapped in. And given that the majority of people are shifting over to Epic, achieving it only requires one easy extra click.
Sarah James
analystNice work on yet one more strong quarter. I truly hate that you're leaving, though Anthony, I'm genuinely eager to see what you do in your new role. You've clearly been bringing a remarkable number of fresh contracts aboard. What's your thinking on how you pace those additions? Do any bottlenecks or trade-offs exist when it comes to the speed of revenue growth? And when we try to build a bridge from 2022 into 2023, what ramp do those newly announced contracts imply once annualized?
Stan Vashovsky
executiveI'll take the first crack at it, and Anthony, perhaps you can wrap it up; over these past 3, 4 years we've worked our way through plenty of obstacles. One thing we've become really good at, you know, is standing up big projects fast. I'd say we're a first call for many cities and many major hospital networks across the nation that must get a program going, and they prefer doing so at a large scale, and they want it done fast. On the recruiting side, we've got procedures that let us bring people on and bring in outside staffing firms when necessary; again and again we've gotten projects running within weeks when rivals of ours would need months, and those projects frequently involve hundreds of medical staff. That's a piece of what makes our formula special. We do give folks a few hints, but even so, it remains fairly proprietary. Over what I believe is now 8 quarters of reporting, I think we've shown we can grow and grow well even in the toughest circumstances. First came the COVID stretch when folks didn't want to show up for work, next came the wave of mass resignations, then all the various cycles we've been through across these past several years. We've been quite lucky to have leadership so committed to steering us through it all. Anthony, is there anything more you'd like to add there?
Anthony Capone
executiveRight, so on that point — at this moment we haven't put out any guidance for 2023, which means I can't say precisely how the ramp is going to play out. But here's what I can share: as Stan mentioned, we've gotten really good at starting with a contract that's often on the smaller side and expanding it into something quite substantial. We've done this many times before, and it comes down to one straightforward idea — we go above and beyond what's promised, and we're consistently quick to respond whenever our customers need us.
Sarah James
analystThanks. Building on that, you brought up the pilot you've got going with Cigna. What's your view on how long a standard assessment window typically lasts before expansion becomes something you can talk about, and which kinds of benchmarks do your partners want to see, in terms of proving performance and being ready to have those expansion discussions?
Stan Vashovsky
executiveWell, you know, the entirety of this year really serves as the evaluation phase for us. We're taking baby steps and carefully working out precisely what shape we want our B2C program to take. As you're aware, nearly every company that has entered B2C bleeds money, then they wind up pivoting toward becoming B2B organizations; we're determined not to repeat those errors; we already have a fairly strong company operating as B2B today. A B2C future and strategy appeals to us a great deal, but we'll pursue it with tremendous caution, keeping a very close watch on the single most important metric, the customer acquisition cost. My sense is that our payer relationships, Cigna among them along with a number of others, during 2022 will primarily serve to validate business processes and concepts, plus financial models. Only once those results satisfy us will we commit fully, and we're getting ready for that full commitment, since we're quite pleased with certain results we've observed year to date, and you'll see that at some point, ideally in 2023.
Stan Vashovsky
executiveRichard, good to have you back.
Richard Close
analystYes, thank you for asking, and my apologies — sorry about that. Appreciate the question. So, as you're aware, we've held quite a few conversations with investors, and there seems to be a bit of confusion, I suppose, regarding the DocGo narrative. I figured it might be helpful if you said a few words about utilization. You know, many companies have pointed to softening utilization patterns. Others have flagged labor headwinds, shortages, retention issues, wage pressure. Some investors come to me asking why DocGo, you know, doesn't appear to face any of that. Could you speak a bit about your business when it comes to, you know, those softer utilization patterns, the labor headwinds, and perhaps why you're shielded from them?
Stan Vashovsky
executiveAlright, I'll kick things off, and then hand it over to Anthony, Richard. Basically, our business models are quite distinct from those of our rivals. Bear in mind, healthcare has been my field for 30 years, so this isn't my first time around the block. When mobile health was getting off the ground, we recognized right from the start that entering the traditional fee-for-service space — where you're pulling reimbursement from Medicare, Medicaid, commercial MA plans — means you'll face limits on precisely what you can collect and the manner in which you collect it. That's a business model we had no interest in pursuing. We came up with the idea of a lease, which we refer to as our leased labor plan. Our approach is to assemble a complete clinical program; we bill a per-day rate for each clinician; every one of them is dedicated staff trained for a particular project. While we're in the field, we additionally have modest up charges tied to various, let's say, procedures or tests we perform. Quite often, depending on outcomes, we receive a bonus payment too, as Anthony brought up before; we aren't a conventional fee-for-service operation. Ours is simply, let's call it, leased hour headcount, billed monthly or on a quarterly basis depending on what the contract says. These staff members are dedicated; the burden of utilization falls on our customer, not on us. Suppose we have, say, 15 physician assistants performing pre-op services inside patients' homes for a hospital — that hospital is the party that fills their schedules through our tech platform. That hospital is the one deciding who receives priority and who does not. Should we determine more staff are needed, we'll bring them on. We'll recommend adding them. If demand appears weaker, we'll suggest cutting that headcount for the next quarter. The whole business plan is extremely, extremely different. We aren't a conventional fee-for-service outfit. On top of that, we can renegotiate our rates far more often. Were I a typical fee-for-service company accepting reimbursements from United or Aetna, and my labor costs along with my fuel costs rose, my ability to approach Aetna or United and renegotiate that reimbursement would be quite constrained. It's a totally different story when I have a hospital I partner with, since I could approach them at year's end and adjust my pricing in light of inflationary pressures. At the core of the business, it's very different. We do essentially no fee-for-service. Ours is a substantially different business model, built around lease hour plus additional up charges for various procedures we carry out. It's a dedicated staff model, and the hospitals, the municipalities, the commercial accounts we serve truly view us as an extension of their own team rather than merely a vendor. I believe that's yet another factor behind our very strong customer renewal rates, along with our success rates. I think that covers what you were asking. Anthony, is there anything you'd like to add?
Anthony Capone
executiveOne thing I'd like to mention is the level of quality that results from this, something Stan touched on. I truly can't stress enough how significant that is. Under a conventional fee-for-service arrangement, it's certainly simpler—for the end healthcare organization you're signing a contract with—to perhaps secure a lower price if they merely attempt to pit a group of individuals against one another and go the fee-for-service route. What you end up with in terms of care quality is far worse; that creates every kind of issue later on. When you provide folks with these devoted resources—whatever those resources happen to be doing, whatever your approach is, whatever those resources might be—the final outcome, the standard of care that ultimately gets provided, is considerably better. Clients notice this, retention rises, and clearly, our margins stay safeguarded as well.
Stan Vashovsky
executiveRichard, this initiative was something we introduced a couple of years back, and at this point we've got more than 4,000 employees, with most of them working under that program.
Richard Close
analystCould you say a bit about how well you're keeping your staff? I'm aware that in home health, for instance, the workforce shrinking has hit that area hard. Could you discuss your capacity when it comes to labor, and perhaps share what your retention rate looks like? There are folks asking why your labor picture doesn't mirror what's happening elsewhere.
Stan Vashovsky
executiveOkay, so I'll jump in first with an answer, and then hand things off to Anthony. Particularly on that retention figure. To start with, regarding our people, I'd say we treat our team well. For starters, our pay is roughly 10%-15% hourly. Hourly wages run around 10%-15% above Street. We also give staff incentives to perform at their best out in the field, and then we're able to award bonuses tied to customer satisfaction scores. Pretty much every full-time person here is included in the company equity plan; we put a substantial amount toward educating employees. So if you combine all those pieces, we operate somewhat differently from a typical company. Our Glassdoor and Indeed scores probably say it best. Ours is the top Glassdoor rating in the sector, sitting around 4.2, 4.3. Happy workers, we've found, perform better in the field, and they bring their friends to us too. That's a boost for recruiting. On the subject of retention, our approach to measuring it differs quite a bit from what many other employers do. Let me hand it to Anthony now so he can explain what we track.
Anthony Capone
executiveOkay, super fast. If you're a traditional company, you tend to measure retention by days, or maybe months or years — some kind of time period. To us, that's completely illogical. Our lens is money. What amount of revenue does a typical worker generate across the various categories, compared with what it cost to bring that person aboard, and roughly what return do we get on the value of that initial hire? That's our method of evaluation, and we track everything across this company, and in that area we're improving, not declining. Our model is quite distinctive, and it lets us raise revenue per employee against the upfront expense for each and every one of those workers. Now, one factor behind this — and one factor that lets us compensate better than most in the industry — ties back to what you asked earlier. If you've got committed staff who are compensated by the hour, and we're able to manage our margins, then we're in a position to offer a higher rate than those who typically operate on a fee for service arrangement. Take the home health agencies you used as an example — they're generally close to 100% fee for service, which means demand swings a lot, plus idle time, so their margins get squeezed, and they're able to pay comparatively little. With our model, where you've got a committed healthcare resource, you can just pay more, since your margins are shielded. That's a dramatically different approach, and it extends all the way to how you compensate your staff.
Stan Vashovsky
executiveWhat matters is that compensation isn't the only piece. There are multiple factors we examine regarding our employees and our staff, and those factors get weighed. Within human resources, we've got groups of individuals dedicated to how satisfied employees feel, and that's an area we monitor extremely carefully. If you combine multiple factors, ideally the result is a content workforce that chooses to remain with the company, and ideally those employees will also want to recommend others to join us.
Kieran Ryan
analystHey everyone. Kieran Ryan here, filling in for Pito. Appreciate you taking my question. When we look at 3Q margins, they arrived quite robust, slightly north of 8%. With the revenue beat, I figured perhaps there might be a bit additional room to the upside. Since fuel and labor costs are, per your comments, monitoring consistent with what you'd anticipated, would it be reasonable to view these new contract upstart costs as essentially the primary gross margin swing element for 3Q, and then likewise for the increase as we move into 4Q?
Stan Vashovsky
executiveYes; that is precisely what we'd be examining. As stated in our release, mass COVID testing revenue during the same period a year ago accounted for roughly 35% of revenue, and currently it sits in mid single digits. Essentially, that means numerous new contracts got implemented over the course of the third quarter. Three specific contracts, two hospitals plus one municipality, were quite sizable, and what I'd describe as long-term agreements have kicked off. There's a start-up cost tied to contracts of that nature; typically, you know, we'd experience it for around 60, occasionally 90 days, yet afterward we enjoy multiple years of returns from that initial investment. Excluding those initial start-up costs incurred for the three large customers, EBITDA margins would have come in considerably higher. I actually view that as a good expense. I'd gladly, you know, see that on a quarterly basis. It signals we're signing more long-term profitable contracts.
Kieran Ryan
analystThat's helpful. Thank you. Just quick follow-up.
Stan Vashovsky
executiveSure.
Kieran Ryan
analystIn the past, I believe you mentioned that LPNs were coming in at roughly 65%-70% of what RNs cost, speaking in general terms. Of course, I'd imagine that varies considerably from one region to another. Is that still broadly the correct figure, and is there anything different in the hiring landscape you could point to across the last three months? Thank you.
Stan Vashovsky
executiveYeah. The precise percentage for what LPNs cost, I'll let Anthony or Norm or Andre address that. The reality is we have hundreds of physician assistants, nurse practitioners, registered nurses, and LPNs. Andre or Anthony, do you know where the LPNs are tracking relative to RNs? Is that a topic you're at liberty to discuss?
Anthony Capone
executiveRight, and I’d say the figure you mentioned — 65% — is in the ballpark. That’s about right. I can’t give you the exact percentage, but my sense is that it’s pretty close.
Stan Vashovsky
executiveMy guess is that location plays a role in this too. Of course there are variations — for instance, wages differ quite a bit between somewhere like New York City and, say, Nashville, Tennessee — yet typically they stay fairly similar when compared on a relative basis. I think the main point, and one reason our model, in my view, has worked better, is simply that LPNs greatly outnumber RNs, and RNs greatly outnumber, you know, APPs, you know, independent licensed practitioners.
Michael Latimore
analystYeah, thank you.
Stan Vashovsky
executiveHi, Mike.
Michael Latimore
analystCongratulations, Stan, and greetings. Best wishes to you both regarding the new positions you've taken on. That sounds thrilling.
Stan Vashovsky
executiveI appreciate it.
Michael Latimore
analystYeah, regarding the mobile transport segment, it rose quite a bit from one quarter to the next. Could you say a bit about what caused that, and then, you know, sort of a fresh baseline to consider?
Stan Vashovsky
executiveYeah. Anthony, do you want to take that?
Anthony Capone
executiveYes. It's really come from two things working together — our capacity to pick up licenses, and then our capacity to make money from them. Take the case I mentioned: we got a SCT license — that stands for specialty care transport license — in New Jersey, through a business named Exceptional Medical Transport. Right away, we could, you know, take that Exceptional Medical Transport and use it to serve the Jefferson Health customer we already had. That sort of model is largely, you know, what we've been seeing. The growth we've seen comes from examining the customer base we already have and telling ourselves, "Look, there's revenue we can't capture since we lack a competency, a capability, a licensure, or possibly every one of those." So we go out and locate a value buy to serve it. Broadly speaking, that's more or less how our tuck-in acquisition strategy works, pretty much across the board. I'd say that, yes, I think, Andre, you could add more on whether this is a new baseline from here on out. You know, the revenue we get from transport recurs and is entirely part of, you know, multi-year contracts that have stood for a long time.
Stan Vashovsky
executiveYes, I'd like to build on Anthony's comments. At the top tier of transportation, such as SCT, which was designed to boost our typical price for each trip on contracts outside the leased-out program by roughly 20% this year compared with last year — that's approximately right, and I believe you'll find it in the 10-Q tomorrow. Back in 2021, the typical expense for each trip came to around $303, while this year it's roughly $374. That works out to an increase of about 23%, simply because we now have this elevated transportation capability thanks to those tuck-in acquisitions.
Michael Latimore
analystAll right, that's excellent; when it comes to the climate for spending among cities and towns, it sounds like things are fairly robust on the whole, but could you sort of describe what you're picking up from local governments regarding, you know, their appetite for launching new initiatives or growing existing ones and, you know, how they see perhaps the coming year shaping up?
Stan Vashovsky
executiveYou know, there's enormous national attention right now on population health. I believe our country has at last reached a point where people understand that to hold down Medicaid and Medicare expenses, you need to take a proactive approach to ensuring healthcare is available to all. We're a big part of that; our offering is highly cost-efficient and comes with documented, proven outcomes. Our expectation is that population health and government-style initiatives will keep growing. No indication of any deceleration has appeared — quite the reverse. We've got several new contracts lined up for the upcoming quarter. You know, that genuinely excites me. I think America is at last adopting some forward-looking steps to get ahead of this issue rather than merely responding to it. I'm also quite proud that our offering serves those particular requirements. An offering that's quite inexpensive, one that just makes sense since we utilize medical clinicians who are well trained with truly cutting-edge equipment. Pair that with telemedicine, and you wind up with, you know, something quite distinctive, a massive point of differentiation. You're merging the finest in medicine with the finest in technology to ultimately produce strong, positive results. That's the foundation of our business.
David Grossman
analystThank you. Good afternoon.
Stan Vashovsky
executiveHi, David.
David Grossman
analystHey Stan, that topic came up on a couple of occasions. I believe both you and Anthony brought up this notion of landing and then expanding inside your customer base. Could you share any insight on what same-store sales growth is trending at, percentage-wise, just so we can dimension your capacity to expand successfully within that base?
Stan Vashovsky
executiveWell, I’m not sure whether we’ve put out specific figures on that, David, but what I can say is that for me, holding onto same-store sales has always been a lot harder than simply going out and continuing to sell, continuing to turn customers over. To be honest, I can’t think of any programs—what I’d describe as material ones—that we’ve actually lost over the past 2 years. Our programs tend to be extremely sticky. A big part of that comes down to the technology we bring in. We’re a highly integrated company. We connect with most of the big EMR offerings on the market. Once you’ve gone through that kind of work, you usually end up being a long-term partner to that institution. I’d say that’s a very big number. I don’t believe we reveal the exact share of our growth that comes from same-store sales across the country. We keep bringing on new customers, but what makes me proudest is that we don’t lose the ones we already have, and those existing customers return to us with fresh ideas they want to put in place. Quite often, we’re the organization they turn to first when those new ideas come up. We toss around some possible ways to get those things done. Then we shape that into a proposal. In many cases—and I think this is something distinctive about our business model that many others don’t do—we’ll start a program, and as long as compliance gives approval, we won’t bill anything, or we’ll bill only cost, for 30, 60 days, so the customer can see what the results look like. If they’re happy with those results, we then move into a longer-term contract. We don’t use the kind of high-pressure approach where you sign a 3- or 5-year deal and take on risk. Ours is a soft sale. Give it a try for 30 days, 60 days. See whether you like what you get. If you do, then let’s move forward into a longer relationship. Once again, I’d repeat that the vast majority of our growth has come through same-store sales. At the same time, since Lee Bienstock came to us from Google, we’ve done a strong job bringing new leads in the door, answering new RFPs, and getting new contracts signed too.
Stan Vashovsky
executiveThat's really all. I truly want to express gratitude to everybody for being here tonight. I realize the hour is late. It has genuinely been a privilege to collaborate with so many of these fantastic analysts and, you know, folks in finance from the financial world. I sincerely believe DocGo is accomplishing something great. We're approaching it in our own way, and I think the numbers we've posted speak for themselves. I've consistently maintained that you should evaluate us based on outcomes, not slides. My hope is that someday we'll reach that point. I just want to convey how much I value everyone's backing. Thanks to all of you for being here tonight, and with that, this phone call comes to an end. Thank you, everyone.
Operator
operatorThis concludes today's conference call. You may disconnect your lines. Thank you for participating.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.